Nature‐Inspired MYC Inhibitor Disrupts MYC‐Driven Glycolysis and Restricts Ovarian Tumor Growth
ChemMedChem · 2026
DOI: 10.1002/cmdc.202500554 ↗At a glance
Journal article in ChemMedChem, 2026. Written by Mamta Singh and 13 co-authors. Institution: Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Uttar Pradesh, 201313, India. Major MEDLINE topics: Ovarian Neoplasms, Glycolysis, Proto-Oncogene Proteins c-myc, Antineoplastic Agents. 38 references.
Abstract (original language)
Myelocytomatosis oncogene (MYC) inhibitors are not available for clinical applications because the MYC protein is not part of a receptor‐ligand pair and lacks a defined binding site for small molecules. GD‐07, drug‐like small molecule identified throughcheminformatics that selectively binds to the G‐quadruplex (G4) in the c‐MYC promoter with high binding affinity and selectivity over dsDNA. NMR analysis reveals that GD‐07 binds to the upper tetrad of c‐MYC G4. It exhibits a favorable pharmacokinetic profile and high cytotoxicity in ovarian cancer (OC) cells (A2780) compared to the standard drug carboplatin. Normal cells show no sensitivity to GD‐07, indicating a broad therapeutic window. GD‐07 suppresses MYC expression, curbing glucose metabolism, and glycolysis while promoting p53 and proapoptotic markers in OC cells. In patient‐derived OC organoids, GD‐07 shows greater activity than carboplatin with promising clinical translatability.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Uttar Pradesh, 201313, India.
- Department Biosciences and Bioengineering, Indian Institute of Technology Bombay, IIT Bombay, Powai, Mumbai, 400076, India.
- Department of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, 30172, Venice, Italy.
- Pathology Unit, Centro di Riferimento Oncologico di Aviano (C.R.O.) IRCCS, 33081, Aviano, Italy.
- Department of Chemistry, Indian Institute of Science Education and Research, Bhopal, 462 066, India.
- Graduate School of Nanobioscience, Yokohama City University, 22-2 Seto Kanazawa-ku, Yokohama, 236-0027, Japan.
ORCID profiles: Reshma Rani
Cite
APA
Singh, M., Yadav, A., Singh, U., Gupta, R., Cavarzerani, E., Canzonieri, V., Negi, D., Dagar, A., Sathyamoorthy, B., Rizzolio, F., Kumar, S., Baliyan, A., Rani, R., & Kumar, V. (2026). Nature‐Inspired MYC Inhibitor Disrupts MYC‐Driven Glycolysis and Restricts Ovarian Tumor Growth. ChemMedChem. https://doi.org/10.1002/cmdc.202500554
Vancouver
Singh M, Yadav A, Singh U, Gupta R, Cavarzerani E, Canzonieri V, et al. Nature‐Inspired MYC Inhibitor Disrupts MYC‐Driven Glycolysis and Restricts Ovarian Tumor Growth. ChemMedChem. 2026. doi:10.1002/cmdc.202500554
BibTeX
@article{Singh2026,
author = {Singh, Mamta and Yadav, Anubha and Singh, Umesh and Gupta, Rajat and Cavarzerani, Enrico and Canzonieri, Vincenzo and Negi, Deepraj and Dagar, Akansha and Sathyamoorthy, Bharathwaj and Rizzolio, Flavio and Kumar, Sushil and Baliyan, Ankur and Rani, Reshma and Kumar, Vinit},
title = {Nature‐Inspired MYC Inhibitor Disrupts MYC‐Driven Glycolysis and Restricts Ovarian Tumor Growth},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.202500554}
}
EUVIMED